Surfactant replacement therapy. A major breakthrough in neonatal medicine;Surfactantsubstitutionstherapie. Ein entscheidender durchbruch in der behandlung des atemnotsyndroms frühgeborener

Monatsschrift fur Kinderheilkunde

Volumn 150, Issue 6, 2002, Pages 659-668

  Speer, C P ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Preterm infants; Prophylaxis; Pulmonary surfactant; Rescue; Respiratory distress syndrome

Indexed keywords

LUNG SURFACTANT;

ARTICLE; CHRONIC LUNG DISEASE; HUMAN; LUNG DISEASE; MECONIUM ASPIRATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN CARE; NEWBORN DISEASE; PNEUMONIA; TREATMENT OUTCOME;

EID: 2442425653     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-002-0434-y     Document Type: Article

References (73)

1. Ainsworth SB, Beresford MW, Milligan DWA et al. (2000) Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 355: 1387-13-92
2. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97: 517-526
3. Bevilacqua G, Halliday HL, Parmigiani S, Robertson B (1993) Randomized multicenter trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome. J Perinat Med 21: 329-340
4. Berggren E, Liljedahl M, Winbladh B et al. (2000) Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 89: 460-464
5. Blennow M, Jonsson B, Dahlstrom A et al. (1999) Lung function in premature infants can be improved. Surfactant therapy and CPAP reduce the need of respiratory support. Lakartidningen 96: 1571-1576
6. Bloom BT, Kattwinkel J, Hall RT et al. (1997) Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 100: 31-38
7. Chida S, Phelps DS, Soll RF et al. (1991) Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and with out surfactant treatment. Pediatrics 88: 84-89
8. 4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 153: 404-410
9. Curstedt T (2000) Future surfactant preparations. Biol Neonate 78: 233-268
10. Dekowski SA, Holtzman RB (1998) Surfactant replacement therapy: An update on applications. Pediatr Clin North Am 45: 549-573
11. Dunn M (1993) Surfactant replacement therapy: prophylaxis or treatment? Pediatrics 92: 148-150
12. Egberts J (1995) Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant (Curosurf®). Pharmacoeconomics 8: 324-342
13. Egberts J, Brand R, Walti H et al. (1997) Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 100: 1/e4
14. Enhorning G, Robertson B (1972) Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 50: 58-66
15. Ferrara TB, Hoekstra RE, Couser RJ et al. (1994) Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy. J Pediatr 124: 119-124
16. Findlay RD, Taeusch W, Walther FJ (1996) Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97: 48-52
17. Fok TF, Al-Essa M, Dolovich M et al. (1998) Nebulisation of surfactants in an animal model of neonatal respiratory distress. Arch Dis Child 78: F3-F9
18. Fujiwara T, Maeta H, Chida S et al. (1980) Artificial surfactant therapy in hyaline-membrane disease. Lancet 1: 55-59
19. Gortner L, Pohlandt F, Bartmann P et al. (1994) High-dose versus low-dose bovine surfactant treatment in very premature infants. Acta Paediatr 83: 135-141
20. Gortner L, Wauer RR, Hammer H et al. (1998) Early versus late surfactant treatment in preterm infants of 27 to 32 weeks of gestational age: a multicenter controlled clinical trial. Pediatrics 102: 1153-1160
21. Griese M, Tredano M, Bahuau M (2001) Pulmonale Alveolarproteinosen - Molekulare Grundlagen und Konsequenzen für Diagnostik und Therapie. Monatsschr Kinderheilkd 149: 1245-1261
22. Haefner D, Germann PG, Hauschke D (1998) Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am J Respir Crit Care Med 158: 270-278
23. Halliday HL (1992) Follow up data from babies treated with surfactant. In: Bevilacgua G, Parmigiani S, Robertson B (eds) Surfactant in clinical practice. Harwood Academic Publishers, Chur, pp 149-156
24. Halliday HL (1996) Natural versus synthetic surfactants in neonatal respiratory distress syndrome. Drugs 51: 226-237
25. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC (1993) Multicenter randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 69: 276-280
26. Halliday HL, Speer CP, Robertson B (1996) Treatment of severe meconium aspiration syndrome with porcine surfactant. Eur J Pediatr 155: 1047-1051
27. Hallman M, Vainionpää L (2000) Infants born very premature - more prospective studies needed Acta Paediatr 89: 1149-1154
28. Hallman M, Glumoff V, Rämet M (2001) Surfactant in respiratory distress syndrome and lung injury. CBP 129: 287-294
29. Hellstrom-Westas L, Bell AH, Skov L et al. (1992) Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics 89: 643-647
30. Herting E (1997) Sekundärer Surfactant-Mangel bei respiratorischer Insuffizienz im Neugebore-nenalter - Experimentelle und klinische Untersuchungen zur Pathogenese des Mekonium-Aspirations-Syndroms und der konnatalen Pneumonie. Habilitationsschrift, Fachbereich Medizin, Georg-August-Universität Göttingen
31. Herting E, Tubman R, Halliday HL et al. (1993) Einfluß von 2 unterschiedlichen Dosierungen eines porcinen Surfactants auf den pulmonalen Gasaustausch Frühgeborener mit schwerem Atemnotsyndrom. Monatsschr Kinderheilkd 141: 721-727
32. Herting E, Gefeller O, Land M et al. (2000) Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106: 957-964
33. Herting E, Rauprich P, Stichtenoth G et al. (2001) Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 50: 44-49
34. Ingimarsson J, Björklund L, Jonson B et al. (2000) A radio-isotope technique for visualisation of exogenous surfactant spreading in immature lamb lungs at birth. Biol Neonate 77: 21-28
35. Jobe AH (2000) Which surfactant for treatment of respiratory-distress syndrome. Lancet 355: 1380-1381
36. Jorch G, Hartl H, Roth B et al. (1997) Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol 24: 222-224
37. Kari MA, Hallman M, Eronen M et al. (1994) Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 93: 730-736
38. Kattwinkel J (1998) History and current understanding of surfactant. Clin Perinatol 25: 17-32
39. Konishi M, Fujiwara T, Naito T et al. (1988) Surfactant replacement therapy in neonatal respiratory distress syndrome. A multicenter, randomized clinical trial: comparison of high versus low-dose of surfactant TA. Eur J Pediatr 147: 20-25
40. Lam BCC (1999) Surfactant lavage for the management of severe meconium aspiration syndrome. Biol Neonate 76: 10-14
41. Lotze A, Mitchell BR, Bulas DI et al. (1998) Multicenter study of surfactant (Beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 132: 40-47
42. Moen A, Yu XQ, Almaas R et al. (1998) Acute effects on systemic circulation after intratracheal instillation of Curosurf or Survanta in surfactant-depleted newborn piglets. Acta Paediatr 87: 297-303
43. Moriette G, Paris-Llado J, Walti H et al. (2001) Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics 107: 363-372
44. Pandit PB, O'Brien K, Asztalos E et al. (1999) Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant. Arch Dis Child 81: F40-F44
45. Raju TN, Langenberg P (1994) Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr 124: 830-831
46. Rauprich P, Möller O, Walter G et al. (2000) Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clin Diagn Lab Immunol 7: 817-822
47. Robertson B (1996) New targets for surfactant replacement therapy: experimental and clinical aspects. Arch Dis Child 75: F1-F3
48. Robertson B, Johansson J, Curstedt T (2000) Synthetic surfactants to treat neonatal lung disease. Mol Med Today 6: 119-124
49. Rufer R (1967) Der Einfluss oberflächenaktiver Substanzen auf Entfaltung und Retraktion isolierter Lungen. Pflügers Arch 298: 170
50. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ (1994) Effect of surfactant on morbidity, mortality, and ressource use in newborn infants weighing 500 to 1500 g. N Engl J Med 330: 1476-1480
51. Segerer H, Gelder W van, Engement FWM et al. (1993) Pulmonary distribution and efficacy of exogenous surfactant in lung lavaged rabbits are influenced by the instillation technique. Pediatr Res 34: 490-494
52. Soil RF (2000) Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2:CD001079
53. Soil RF, Blanco F (2001) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2: CD 000144
54. Soil RF, Morley O (2000) Prophylactic versus selective use of surfactant for peventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2: CD 000510
55. Speer CP (2001) New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 79: 205-209
56. Speer CP Halliday HL (1994) Surfactant therapy in the newborn. Curr Paediatr 4: 5-9
57. Speer CP, Harms K, Herting E et al. (1990) Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung Suppl: 870-876
58. Speer CP Robertson B, Curstedt T et al. (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89: 13-20
59. Speer CP, Gefeller O, Groneck P et al. (1995) Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 72: F8-13
60. Speer CP, Robertson B, Halliday HL (2000) Randomized trial. comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 89: 510-512
61. Sun B, Curstedt T, Lindgren G et al. (1997) Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Respir J 10: 1967-1974
62. Sweet DG, Halliday HL (1999) Current perspectives on the drug treatment of neonatal respiratory distress syndrome. Paediatr Drugs 1: 19-30
63. Taeusch W, Lu KL, Goerke J, Clements J (1999) Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 159: 1391-1395
64. Tashiro K, Kobayashi T, Robertson B (2000) Dextran reduces surfactant inhibition by meconium. Acta Paediatr 89: 1439-1445
65. Valls-i-Soler A, Fern-ndez-Ruanova B, López-Heredia y Goya J et al. (1998) A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. Pediatrics 101: 4/e4
66. Verder H, Robertson B, Greisen G et al. (1994) Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 331: 1051-1055
67. Verder H, Albertsen P, Ebbesen F et al. (1999) Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks of gestation. Pediatrics 103: E24
68. Walti H, Paris-Llado J, Egberts J et al. (in press) Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular hemorrhage in premature infants. Biol Neonate in press
69. Wang Y, Griffiths WJ, Curstedt T, Johansson J (1999) Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof. FEBS Letters 460: 257-262
70. Wiswell TE (2001) Advances in the treatment of the meconium aspiration syndrome. Acta Paediatr [Suppl] 436: 28-30
71. Wright JR (1997) Immunomodulatory functions of surfactant. Physiol Rev 77: 931-962
72. Zola EM, Gunkel JH, Chan RK et al. (1993) Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 122: 453-459
73. Zola EM, Overbach AM, Gunkel JH et al. (1993) Treatment investigational new drug experience with survanta (Beractant). Pediatrics 91: 546-551